Literature DB >> 21170738

Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.

A Sellami1, H Sellami, S Néji, F Makni, S Abbes, F Cheikhrouhou, H Chelly, M Bouaziz, B Hammami, M Ben Jemaa, S Khaled, A Ayadi.   

Abstract

UNLABELLED: Invasive candidiasis has emerged as an important nosocomial infection, causing significant morbidity and mortality especially among critically ill patients. The aim of our study was to determine specie distribution and resistance profiles of Candida species isolated from blood cultures.
MATERIALS AND METHODS: We conducted a retrospective study of all episodes of candidemia diagnosed in our laboratory from January 2006 to May 2009. The susceptibility to antifungal agents of all Candida isolates was tested by using a Sensititre(®) YeastOne panel.
RESULTS: A total of 130 Candida isolates were recovered from blood cultures. Candida tropicalis was the most frequent specie (37.7%), followed by C. albicans (22.3%), C. glabrata (19.2%), and C. parapsilosis (12.2%). All the isolates were inhibited by ≤1 μg/ml of amphotericin B and ≤2 μg/ml of caspofungin. For fluconazole, 7.3% of clinical isolates were resistant. It was most active against C. parapsilosis (100% susceptible), C. albicans (95.8% susceptible), and C. tropicalis (94% susceptible). All of the fluconazole-susceptible isolates were susceptible to voriconazole, as were 83.3% of the fluconazole-susceptible-dose-dependent isolates. Among fluconazole-resistant isolates, 85.7% were susceptible to voriconazole.
CONCLUSIONS: In our institution, C. tropicalis was the most frequent specie isolated from the bloodstream. Caspofungin had an excellent in vitro activity against Candida isolates and was the drug of choice among fluconazole-resistant isolates. © Springer Science+Business Media B.V. 2010

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170738     DOI: 10.1007/s11046-010-9388-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  33 in total

1.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals.

Authors:  A L Colombo; M Nucci; R Salomão; M L Branchini; R Richtmann; A Derossi; S B Wey
Journal:  Diagn Microbiol Infect Dis       Date:  1999-08       Impact factor: 2.803

3.  Candida glabrata fungemia: experience in a tertiary care center.

Authors:  Anurag Malani; Jareer Hmoud; Loretta Chiu; Peggy L Carver; Andrew Bielaczyc; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2005-08-24       Impact factor: 9.079

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Authors:  Lena Rós Asmundsdóttir; Helga Erlendsdóttir; Magnús Gottfredsson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

6.  Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001.

Authors:  Michael Ellis; Ulla Hedstrom; Pauline Jumaa; Abdulbari Bener
Journal:  Med Mycol       Date:  2003-12       Impact factor: 4.076

7.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

8.  Candida dubliniensis: first identification in Sfax Hospital, Tunisia.

Authors:  M Khlif; H Sellami; A Sellami; H Chelly; F Makni; M Bouaziz; A Ayadi
Journal:  Mycoses       Date:  2008-06-03       Impact factor: 4.377

9.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

Authors:  Mikkel Krogh-Madsen; Maiken Cavling Arendrup; Lars Heslet; Jenny Dahl Knudsen
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

10.  Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals.

Authors:  Marcio Nucci; Arnaldo L Colombo
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03-26       Impact factor: 2.803

View more
  10 in total

1.  Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience).

Authors:  Bilgul Mete; Esra Yerlikaya Zerdali; Gokhan Aygun; Nese Saltoglu; Ilker Inanc Balkan; Ridvan Karaali; Sibel Yildiz Kaya; Berna Karaismailoglu; Abdurrahman Kaya; Seval Urkmez; Gunay Can; Fehmi Tabak; Recep Ozturk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-15       Impact factor: 3.267

2.  Comparative in vitro activities of fluconazole, voriconazole, and MXP-4509 against Romanian blood yeast isolates.

Authors:  Mihai Mareş; Valentin Năstasă; Florina Moraru Ramona; Bogdan Doroftei; Alina Stefanache
Journal:  Mycopathologia       Date:  2011-07-31       Impact factor: 2.574

3.  Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.

Authors:  Laura Bedin Denardi; Débora Alves Nunes Mario; Erico Silva de Loreto; Cristina Wayne Nogueira; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2013-06-23       Impact factor: 2.574

4.  Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole.

Authors:  Cecília Rocha da Silva; João Batista de Andrade Neto; José Júlio Costa Sidrim; Maria Rozzelê Ferreira Angelo; Hemerson Iury Ferreira Magalhães; Bruno Coêlho Cavalcanti; Raimunda Sâmia Nogueira Brilhante; Danielle Silveira Macedo; Manoel Odorico de Moraes; Marina Duarte Pinto Lobo; Thalles Barbosa Grangeiro; Hélio Vitoriano Nobre Júnior
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  FREQUENCY OF Candida SPECIES IN A TERTIARY CARE HOSPITAL IN TRIANGULO MINEIRO, MINAS GERAIS STATE, BRAZIL.

Authors:  Ralciane de Paula Menezes; Joseane Cristina Ferreira; Walkiria Machado de Sá; Tomaz de Aquino Moreira; Lucivânia Duarte Silva Malvino; Lucio Borges de Araujo; Denise Von Dolinger de Brito Röder; Mario Paulo Amante Penatti; Regina Celia Candido; Reginaldo Dos Santos Pedroso
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 May-Jun       Impact factor: 1.846

6.  Anti-fungal resistance in candida isolated from oral and diaper rash candidiasis in neonates.

Authors:  Jasem Mohamadi; Mahsa Motaghi; Jafar Panahi; Mohamad Reza Havasian; Ali Delpisheh; Mitra Azizian; Iraj Pakzad
Journal:  Bioinformation       Date:  2014-11-27

Review 7.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08

8.  Predominance of Candida Glabrata among Non-albicans Candida Species in a 16-Year Study of Candidemia at a Tertiary Care Center in Lebanon.

Authors:  Aline El Zakhem; Rachid Istambouli; Maria Alkozah; Amal Gharamti; Mohamad Ali Tfaily; Jean-Francois Jabbour; George F Araj; Hani Tamim; Souha S Kanj
Journal:  Pathogens       Date:  2021-01-19

9.  Synthesis, Cytotoxicity Evaluation, and Antifungal Activity of Novel Nitroglycerin Derivatives against Clinical Candida albicans Isolates.

Authors:  Niloofar Rashidi; Sassan Rezaie; Sayed Jamal Hashemi; Aziziollah Habibi; Mohammad Hadi Baghersad; Roshanak Daie; Sadegh Khodavaisy; Heidar Bakhshi; Ali Salimi; Mohammad Ebraim Getso; Zahra Rafat
Journal:  Iran J Public Health       Date:  2021-09       Impact factor: 1.429

10.  Interactions between copy number and expression level of genes involved in fluconazole resistance in Candida glabrata.

Authors:  Salma Abbes; Charles Mary; Hayet Sellami; Annie Michel-Nguyen; Ali Ayadi; Stéphane Ranque
Journal:  Front Cell Infect Microbiol       Date:  2013-11-11       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.